COCH (Envoy Medical) LT-Debt-to-Total-Asset: 0.03 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

COCH Envoy Medical Inc COCH
6 GF Score
Price $0.75
GF Value $0.66
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Envoy Medical LT-Debt-to-Total-Asset?

Envoy Medical COCH +0.30% 6 LT-Debt-to-Total-Asset is 0.03 as of Jun. 2026. GuruFocus rates COCH with a GF Score™ of 6/100 and a GF Value™ of $0.66 (Modestly Overvalued). The stock has 8 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Envoy Medical's long-term debt to total assests ratio for the quarter that ended in Jun. 2026 was 0.03.

Envoy Medical's long-term debt to total assets ratio declined from Jun. 2025 (2.89) to Jun. 2026 (0.03). It may suggest that Envoy Medical is progressively becoming less dependent on debt to grow their business.

Envoy Medical  (NAS:COCH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Envoy Medical LT-Debt-to-Total-Asset Related Terms

Envoy Medical LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Envoy Medical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Envoy Medical LT-Debt-to-Total-Asset Chart

Envoy Medical Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
8.95 13.29 0.05 1.69 0.09

Envoy Medical Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.89 0.10 0.09 0.02 0.03
COCH
6GF Score
Envoy Medical Inc COCH
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Envoy Medical LT-Debt-to-Total-Asset Calculation

Envoy Medical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=0.745/8.558
=0.09

Envoy Medical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2026 is calculated as

LT Debt to Total Assets (Q: Jun. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2026 )/Total Assets (Q: Jun. 2026 )
=0.678/23.949
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.03 mean?
Envoy Medical (COCH) has a LT-Debt-to-Total-Asset of 0.03 as of Jun. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Envoy Medical and its competitors.
Is Envoy Medical's LT-Debt-to-Total-Asset too high?
Envoy Medical's current LT-Debt-to-Total-Asset is 0.03. Overall, Envoy Medical has a GF Score™ of 6/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Envoy Medical's LT-Debt-to-Total-Asset compare to ECOR and MDAI?
Envoy Medical's LT-Debt-to-Total-Asset of 0.03 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Envoy Medical and its competitors. Envoy Medical's current LT-Debt-to-Total-Asset is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Envoy Medical stock overvalued right now?
Based on GuruFocus' analysis, Envoy Medical (COCH) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.66, compared to a current price of $0.75 — trading 13.2% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.03. Envoy Medical's overall GF Score™ is 6/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Envoy Medical (COCH), the current LT-Debt-to-Total-Asset is 0.03 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Envoy Medical (COCH) Overvalued in 2026?

Based on GuruFocus' analysis, Envoy Medical stock appears to be overvalued. The current stock price of $0.75 is trading 13.2% above its estimated GF Value™ of $0.66. GuruFocus considers Envoy Medical to be Modestly Overvalued.

Key valuation signals for COCH:

  • LT-Debt-to-Total-Asset: 0.03
  • GF Value™: $0.66 vs. price of $0.75 (13.2% above fair value)
  • GF Score™: 6/100 with 8 warning signs

No single metric tells the full story. See the COCH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Envoy Medical Business Description

Address 4875 White Bear Parkway, White Bear Lake, MN, USA, 55110
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
6GF Score

Get the complete analysis for COCH

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price
$0.66
GF Value